Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the lives of patients worldwide.
INNOVATIVE TOPICAL THERAPIES FOR MILLIONS OF PATIENTS WORLDWIDE
The Oculis strategy is to build a specialty ophthalmology company unlike any other. Our plan is to further advance our lead candidate, OC-118, for commercialisation as a new therapeutic option for DME patients
and to develop a clinical pipeline of topical treatments for back- and front-of the-eye disease based on internal development with our proprietary SNP technology and via complementary in-licensed assets
OC-118 A POTENTIAL PARADIGM SHIFT IN DME TREATMENT
Our most advanced product candidate based on SNP technology is OC-118, which is in clinical trials in patients with DME and in planning phase for potential front-of-the-eye indications.
If approved in DME, it has the potential to provide a new option for patients for whose current therapies are limited to intravitreal injections or implants.
TAKING TREATMENT FROM INJECTIONS TO DROPS FOR BACK-OF-THE-EYE DISEASES
Our novel technology provides an unprecedented technical advancement in ocular drug delivery, particularly for back-of-the-eye diseases that are currently managed by invasive methods such as intraocular injections or implants.
INNOVATIVE TOPICAL THERAPIES FOR MILLIONS OF PATIENTS WORLDWIDE
The Oculis strategy is to build a specialty ophthalmology company unlike any other. Our plan is to further advance our lead candidate, OC-118, for commercialisation as a new therapeutic option for DME patients
and to develop a clinical pipeline of topical treatments for back- and front-of the-eye disease based on internal development with our proprietary SNP technology and via complementary in-licensed assets
OC-118 A POTENTIAL PARADIGM SHIFT IN DME TREATMENT
Our most advanced product candidate based on SNP technology is OC-118, which is in clinical trials in patients with DME and in planning phase for potential front-of-the-eye indications.
If approved in DME, it has the potential to provide a new option for patients for whose current therapies are limited to intravitreal injections or implants.
TAKING TREATMENT FROM INJECTIONS TO DROPS FOR BACK-OF-THE-EYE DISEASES
Our novel technology provides an unprecedented technical advancement in ocular drug delivery, particularly for back-of-the-eye diseases that are currently managed by invasive methods such as intraocular injections or implants.
Location: Switzerland, Vaud, Lausanne
Employees: 11-50
Total raised: $292.47M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | Earlybird ... | earlybird.... |
| - | VI Partner... | vipartners... |
| - | NFLS - Piv... | pivotalbio... |
| - | Bay City C... | baycitycap... |
Funding Rounds 6
| Date | Series | Amount | Investors |
| 14.02.2025 | - | $100M | - |
| 15.04.2024 | - | $59M | - |
| 12.06.2023 | - | $40M | - |
| 05.05.2021 | Series C | $57M | - |
| 04.01.2019 | Series B | $15.95M | - |
| 05.01.2018 | Series B | $20.52M | Novartis V... |
Mentions in press and media 50
| Date | Title | Description |
| 14.02.2025 | Oculis raises USD 100 million | This Offering follows the release of recent groundbreaking data from the Phase 2 ACUITY trial of OCS-05 (Privosegtor), which has the potential to be the first neuroprotective treatment in ophthalmology, in patients with acute optic neuriti... |
| 09.01.2025 | Positive developments at Swiss biotech companies | Dedicated to combating neglected and hard-to-treat cancers, iOnctura is developing new treatments with precision oral small molecules that target cancers in novel ways. Their lead asset, Roginolisib, is an allosteric modulator of PI3Kδ wit... |
| 14.11.2024 | Shaping the future: Healthtech innovations | Healthtech companies are crucial in shaping the future of healthcare in Europe by providing innovative technologies that improve patient outcomes and healthcare system efficiency. These solutions range from digital tools for health monitori... |
| 30.08.2024 | US and European approvals open new avenues for Swiss Biotechs | Life Molecular Imaging (LMI), a partner of AC Immune has received Fast Track Designation for the Tau positron emission tomography (PET) diagnostic, [18F]PI-2620, from the U.S. Food and Drug Administration (FDA) in three neurodegenerative c... |
| 11.06.2024 | Biotech startups make clinical progress | The U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application from Anaveon to conduct a Phase I/II study evaluating the safety and clinical activity of their drug candidate ANV600. As the company’s... |
| 17.04.2024 | Oculis Shines Bright with $59 Million Funding Round | Oculis, a visionary biopharmaceutical company, has secured a dazzling $59 million in an oversubscribed funding round, propelling its mission to revolutionize eye care. The company's clinical-stage pipeline, brimming with potential, includes... |
| 15.04.2024 | Oculis secures USD 59 Million in oversubscribed offering and debuts on NASDAQ Iceland main market | Oculis secures USD 59 Million in oversubscribed offering and debuts on NASDAQ Iceland main market 15.04.2024 13:55, Rita Longobardi linkedIn facebook twitter instagram youtube --> Oculis, a pioneering ophthalmic biopharmaceutical company... |
| 12.04.2024 | Oculis raises $59 million in oversubscribed round | Oculis is a clinical stage biopharmaceutical company purposefully driven to save sight and improve eye care with clinical-stage pipeline comprising multiple drug candidates in development for eye diseases of high unmet need. The company bo... |
| 22.12.2023 | Clinical progress for three Biotechs | |
| 10.10.2023 | Promising breakthroughs in healthcare |
Show more